stockrow
Friday 6 November 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
25.55
1.45
−5.37%
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Revenue growth
Arcutis Biotherapeutics, Inc.'s revenue growth over the twelve months to 30 September 2026 was 60.0%, down 31.3 percentage points from fiscal 2025 (91.3%). That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 91.3% | (138.40) |
| FY2024 | 229.7% | (1,287.35) |
| FY2023 | 1,517.1% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 45.1% | (14.28) |
| Jun 2026 | 59.3% | (0.74) |
| Mar 2026 | 60.1% | (21.41) |
| Dec 2025 | 81.5% | (40.21) |
| 9 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ABCL AbCellera Biologics Inc. compare | 101.3% |
| ARQT Arcutis Biotherapeutics, Inc. | 60.0% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 59.6% |
| IOVA Iovance Biotherapeutics, Inc. compare | 51.3% |
| TNGX Tango Therapeutics, Inc. compare | 48.3% |
| DNTH Dianthus Therapeutics, Inc. compare | −11.7% |
| RLAY Relay Therapeutics, Inc. compare | −74.3% |
| DFTX Definium Therapeutics, Inc. compare | — |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement